242 related articles for article (PubMed ID: 36753024)
1. Translocations and Gene Fusions in Sinonasal Malignancies.
Larkin R; Hermsen MA; London NR
Curr Oncol Rep; 2023 Apr; 25(4):269-278. PubMed ID: 36753024
[TBL] [Abstract][Full Text] [Related]
2. DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract: clinicopathologic characterization of seven cases with deceptively bland morphology.
Kuo YJ; Lewis JS; Zhai C; Chen YA; Chernock RD; Hsieh MS; Lan MY; Lee CK; Weinreb I; Hang JF
Mod Pathol; 2021 Oct; 34(10):1820-1830. PubMed ID: 34108636
[TBL] [Abstract][Full Text] [Related]
3. DEK-AFF2 Carcinoma of the Sinonasal Region and Skull Base: Detailed Clinicopathologic Characterization of a Distinctive Entity.
Rooper LM; Agaimy A; Dickson BC; Dueber JC; Eberhart CG; Gagan J; Hartmann A; Khararjian A; London NR; MacMillan CM; Palsgrove DN; Nix JS; Sandison A; Stoehr R; Truong T; Weinreb I; Bishop JA
Am J Surg Pathol; 2021 Dec; 45(12):1682-1693. PubMed ID: 34049316
[TBL] [Abstract][Full Text] [Related]
4. Middle Ear and Temporal Bone Nonkeratinizing Squamous Cell Carcinomas With DEK-AFF2 Fusion: An Emerging Entity.
Todorovic E; Truong T; Eskander A; Lin V; Swanson D; Dickson BC; Weinreb I
Am J Surg Pathol; 2020 Sep; 44(9):1244-1250. PubMed ID: 32366754
[TBL] [Abstract][Full Text] [Related]
5. Nuclear expression of AFF2 C-terminus is a sensitive and specific ancillary marker for DEK::AFF2 carcinoma of the sinonasal tract.
Kuo YJ; Lewis JS; Truong T; Yeh YC; Chernock RD; Zhai C; Chen YA; Hongo T; Lee CK; Shi Q; Velez Torres JM; Geromes AB; Chu YH; Hsieh MS; Yamamoto H; Weinreb I; Hang JF
Mod Pathol; 2022 Nov; 35(11):1587-1595. PubMed ID: 35701667
[TBL] [Abstract][Full Text] [Related]
6. DEK::AFF2 Fusion Carcinomas of Head and Neck.
Ruangritchankul K; Sandison A
Adv Anat Pathol; 2023 Mar; 30(2):86-94. PubMed ID: 36221219
[TBL] [Abstract][Full Text] [Related]
7.
Panagopoulos I; Gorunova L; Torkildsen S; Tjønnfjord GE; Micci F; Heim S
Cancer Genomics Proteomics; 2017; 14(6):437-443. PubMed ID: 29109093
[TBL] [Abstract][Full Text] [Related]
8. First Report of Thoracic Carcinoma With DEK::AFF2 Rearrangement: A Case Report.
Savari O; Chang JC; Bishop JA; Sakthivel MK; Askin FB; Rekhtman N
J Thorac Oncol; 2022 Aug; 17(8):1050-1053. PubMed ID: 35773081
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.
Campregher PV; Halley NDS; Vieira GA; Fernandes JF; Velloso EDRP; Ali S; Mughal T; Miller V; Mangueira CLP; Odone V; Hamerschlak N
Leuk Lymphoma; 2017 Dec; 58(12):2969-2972. PubMed ID: 28509585
[No Abstract] [Full Text] [Related]
10. New developments in the molecular pathogenesis of head and neck tumors: a review of tumor-specific fusion oncogenes in mucoepidermoid carcinoma, adenoid cystic carcinoma, and NUT midline carcinoma.
Bhaijee F; Pepper DJ; Pitman KT; Bell D
Ann Diagn Pathol; 2011 Feb; 15(1):69-77. PubMed ID: 21238915
[TBL] [Abstract][Full Text] [Related]
11. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.
French CA; Miyoshi I; Kubonishi I; Grier HE; Perez-Atayde AR; Fletcher JA
Cancer Res; 2003 Jan; 63(2):304-7. PubMed ID: 12543779
[TBL] [Abstract][Full Text] [Related]
12. Role of the DEK oncogene in the development of squamous cell carcinoma.
Ishida K; Nakashima T; Shibata T; Hara A; Tomita H
Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic neoantigens derived from gene fusions stimulate T cell responses.
Yang W; Lee KW; Srivastava RM; Kuo F; Krishna C; Chowell D; Makarov V; Hoen D; Dalin MG; Wexler L; Ghossein R; Katabi N; Nadeem Z; Cohen MA; Tian SK; Robine N; Arora K; Geiger H; Agius P; Bouvier N; Huberman K; Vanness K; Havel JJ; Sims JS; Samstein RM; Mandal R; Tepe J; Ganly I; Ho AL; Riaz N; Wong RJ; Shukla N; Chan TA; Morris LGT
Nat Med; 2019 May; 25(5):767-775. PubMed ID: 31011208
[TBL] [Abstract][Full Text] [Related]
14. The Complexity of DEK Signaling in Cancer Progression.
Teng Y; Lang L; Jauregui CE
Curr Cancer Drug Targets; 2018; 18(3):256-265. PubMed ID: 28530531
[TBL] [Abstract][Full Text] [Related]
15. Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
Chiriches C; Khan D; Wieske M; Guillen N; Rokicki M; Guy C; Wilson M; Heesom KJ; Ottmann OG; Ruthardt M
Ann Hematol; 2022 Oct; 101(10):2179-2193. PubMed ID: 35941390
[TBL] [Abstract][Full Text] [Related]
16. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.
Sandén C; Ageberg M; Petersson J; Lennartsson A; Gullberg U
BMC Cancer; 2013 Sep; 13():440. PubMed ID: 24073922
[TBL] [Abstract][Full Text] [Related]
17. Nonkeratinizing Squamous Cell Carcinoma of the Sinonasal Tract With DEK-AFF2: Further Solidifying an Emerging Entity.
Bishop JA; Gagan J; Paterson C; McLellan D; Sandison A
Am J Surg Pathol; 2021 May; 45(5):718-720. PubMed ID: 33002918
[No Abstract] [Full Text] [Related]
18. Transformation of human CD34+ hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model.
Qin H; Malek S; Cowell JK; Ren M
Oncogene; 2016 Oct; 35(43):5686-5691. PubMed ID: 27065320
[TBL] [Abstract][Full Text] [Related]
19. [Utility of NUT gene expression and rearrangement in diagnosis of NUT midline carcinoma in upper respiratory tract].
Fang W; French CA; Cameron MJ; Han YD; Liu HG
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):519-24. PubMed ID: 23157742
[TBL] [Abstract][Full Text] [Related]
20. Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerization.
Nakashima T; Tomita H; Hirata A; Ishida K; Hisamatsu K; Hatano Y; Kanayama T; Niwa A; Noguchi K; Kato K; Miyazaki T; Tanaka T; Shibata T; Hara A
Cancer Med; 2017 Oct; 6(10):2424-2439. PubMed ID: 28834425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
